Company / Shareholders' Equity
Tvardi Therapeutics, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$57.1M
FY2024
5-year range
$57.1M / $249.0M
FY2020-FY2024
Trend
-74.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from -$54M in FY2015 to $249M in FY2022.
Based on SEC 10-K filings.
$57M in FY2024 with a 5-year CAGR of -8.0%.
Declined from $249M to $57M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -32.6%
- 5-Year CAGR
- -8.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -8.0%, indicating a declining trend.
- In FY2024, shareholders' equity decreased 74.9% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $57.1M | -74.9% |
| FY2023 | $227.5M | -8.6% |
| FY2022 | $249.0M | +33.4% |
| FY2021 | $186.7M | +39.7% |
| FY2020 | $133.6M | +54.0% |
| FY2019 | $86.8M | +71.1% |
| FY2018 | $50.7M | -51.7% |
| FY2017 | $105.0M | +103.3% |
| FY2016 | $51.7M | +195.5% |
| FY2015 | -$54.1M | +7.0% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026